FDA Approves Mirdametinib for NF1-Associated Plexiform Neurofibromas
The FDA has approved mirdametinib for patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas.
Related Articles
Dr Lang on Real-World Outcomes With the KEYNOTE-522 Regimen in Early-Stage TNBC
Julie Lang, MD, discusses real-world outcomes of the neoadjuvant KEYNOTE-522 regimen in patients with early-stage triple-negative breast cancer.
ESMO Plenary on the final OS results from the TROPION-Breast01 trial – OncoDaily
ESMO Plenary on the final OS results from the TROPION-Breast01 trial / cancer, ESMO, ESMO Plenary, OncoDaily, Oncology, TROPION-Breast01 trial
Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer | NEJM
Neuregulin 1 (NRG1) fusions are recurrent oncogenic drivers found in multiple solid tumors. NRG1 binds to human epidermal growth factor receptor 3 (HER3), leading to…
Program Guide – ASCO Meeting Program Guide
Toni Choueiri , Jae Lyun Lee , Jaime Merchan , Amita Patnaik , Benjamin Garmezy , Alexandra Drakaki , Moshe Ornstein , Bradley McGregor ,…
Dr McNall-Knapp on HRQOL Outcomes With Mirdametinib in NF1-PN
Rene Y. McNall-Knapp, MD, discusses HRQOL outcomes from the ReNeu trial investigating mirdametinib in patients with NF1-PN.
Promoting Reasonable Career Expectations and Maximizing Professional Fulfillment for Academic Oncologists: ASCO Recommendations for Academic Medical Centers
In this statement, ASCO encourages academic medical centers to change their policies and expectations to enhance and promote the professional fulfillment of academic medical oncologists.…
Opinion | The Pharmaceutical Industry Heads Into Elon Musk’s Wood Chipper
Who needs N.I.H. grants? A lot of red-state universities, for one.
Comparison of 1-year mortality predictions from vendor-supplied versus academic model for cancer patients
Purpose The Epic End of Life Care Index (EOLCI) predicts 1-year mortality for a general adult population using medical record data. It is deployed at…
Cytoreductive Therapy in PV Treatment Paradigm
Panelists discuss how cytoreductive therapy fits into the treatment paradigm for polycythemia vera (PV), highlighting key findings from the CYTO-PV study and its subanalysis, which…